Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
10:31am, Tuesday, 26'th Nov 2024
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted fo
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
10:30am, Monday, 18'th Nov 2024
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucres
Alnylam downgraded to Underperform from Peer Perform at Wolfe Research
04:41pm, Monday, 11'th Nov 2024
Wolfe Research downgraded Alnylam to Underperform from Peer Perform, citing "unfriendly channel dynamics coupled with inability to rebate."
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
08:00am, Monday, 04'th Nov 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
10:36am, Friday, 01'st Nov 2024
ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
11:26am, Thursday, 31'st Oct 2024
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say
11:01am, Thursday, 31'st Oct 2024
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compa
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates
10:11am, Thursday, 31'st Oct 2024
Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to earnings of $1.15 per share a year ago.
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
08:00am, Thursday, 31'st Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended Se
Seeking Clues to Alnylam (ALNY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:21am, Monday, 28'th Oct 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alnylam (ALNY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qu
Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
09:00am, Sunday, 27'th Oct 2024
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, par
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
11:05am, Thursday, 24'th Oct 2024
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy?
01:01pm, Wednesday, 23'rd Oct 2024
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
